Stock AZT ARCTICZYMES TECHNOLOGIES ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials ArcticZymes Technologies ASA

Equities

AZT

NO0010014632

Biotechnology & Medical Research

Real-time Oslo Bors
Other stock markets
 07:37:01 2024-07-09 am EDT 		5-day change 1st Jan Change
23.35 NOK +1.52% Intraday chart for ArcticZymes Technologies ASA -3.51% -44.40%
Jun. 25 ArcticZymes Technologies Nominates New Chair MT
May. 13 ArcticZymes Technologies ASA Announces Board Resignations CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 229.6 3,074 4,735 3,623 2,137 1,170 - -
Enterprise Value (EV) 1 229.6 3,074 4,552 3,393 1,968 985 964.6 931.3
P/E ratio -39.6 x 37 x 103 x 112 x 114 x 51.2 x 27.8 x 17.8 x
Yield - - - - - - - -
Capitalization / Revenue - 31.4 x 37 x 26.5 x 18 x 8.93 x 7.17 x 5.86 x
EV / Revenue - 31.4 x 35.6 x 24.8 x 16.5 x 7.52 x 5.91 x 4.66 x
EV / EBITDA - - 73.9 x 83.2 x 88.5 x 35.5 x 18.1 x 11.3 x
EV / FCF - - - - 86.5 x 65.7 x 27.6 x 17.2 x
FCF Yield - - - - 1.16% 1.52% 3.63% 5.8%
Price to Book - - 19.3 x 12.7 x 6.92 x 3.55 x 3.15 x 2.67 x
Nbr of stocks (in thousands) 48,335 48,335 50,371 50,571 50,871 50,871 - -
Reference price 2 4.750 63.60 94.00 71.65 42.00 23.00 23.00 23.00
Announcement Date 4/21/20 1/28/21 4/26/22 2/2/23 2/1/24 - - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 97.82 128 137 118.9 131 163.3 199.7
EBITDA 1 - - 61.57 40.8 22.24 27.73 53.23 82.71
EBIT 1 - - 58.43 36.47 15.86 21.54 46.54 78.02
Operating Margin - - 45.65% 26.63% 13.33% 16.44% 28.5% 39.06%
Earnings before Tax (EBT) 1 - - 59 42.14 24.88 15.07 30.08 55.05
Net income 1 -6.386 83.12 46.38 33.11 18.72 23.15 42.58 66.38
Net margin - 84.97% 36.23% 24.17% 15.74% 17.67% 26.08% 33.23%
EPS 2 -0.1200 1.720 0.9100 0.6400 0.3700 0.4494 0.8269 1.290
Free Cash Flow 1 - - - - 22.76 15 35 54
FCF margin - - - - 19.13% 11.45% 21.44% 27.04%
FCF Conversion (EBITDA) - - - - 102.32% 54.1% 65.75% 65.29%
FCF Conversion (Net income) - - - - 121.54% 64.79% 82.2% 81.35%
Dividend per Share 2 - - - - - - - -
Announcement Date 4/21/20 1/28/21 4/26/22 2/2/23 2/1/24 - - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 40.5 49.2 30.36 29.3 28.15 31.19 28.22 31.15 28.38 30.01 30.67 33.92 36.44
EBITDA 1 20.8 27.9 9.539 2.434 0.98 6.117 6.844 7.262 2.017 2.273 6.224 8.503 10.62
EBIT 1 19.98 26.74 8.274 1.53 - 4.527 5.181 5.655 0.495 0.751 4.674 6.953 8.984
Operating Margin 49.33% 54.36% 27.26% 5.22% - 14.51% 18.36% 18.15% 1.74% 2.5% 15.24% 20.5% 24.66%
Earnings before Tax (EBT) 1 19.89 26.69 11.17 3.233 1.049 6.315 7.412 8.435 2.715 4.08 2.847 3.907 4.238
Net income 1 15.44 20.82 8.751 2.492 1.054 5.039 5.604 6.061 2.017 3.169 5.089 6.813 8.093
Net margin 38.12% 42.31% 28.83% 8.51% 3.74% 16.16% 19.86% 19.46% 7.11% 10.56% 16.59% 20.08% 22.21%
EPS 2 0.3000 0.4100 0.1700 0.0500 0.0200 0.1000 0.1100 0.1200 0.0400 0.0600 0.0448 0.0614 0.0685
Dividend per Share 2 - - - - - - - - - - - - -
Announcement Date 4/26/22 4/28/22 8/18/22 10/27/22 2/2/23 5/4/23 8/17/23 11/2/23 2/1/24 5/8/24 - - -
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - 183 230 168 185 205 239
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - 22.8 15 35 54
ROE (net income / shareholders' equity) - - 21.1% 12.5% 6.31% 7.17% 11.8% 15.8%
ROA (Net income/ Total Assets) - - - - - 9.59% 15% 18.4%
Assets 1 - - - - - 241.5 283.4 361.6
Book Value Per Share 2 - - 4.860 5.640 6.070 6.490 7.310 8.600
Cash Flow per Share - - - - - - - -
Capex 1 - - - - 19.2 14.8 27.4 33.5
Capex / Sales - - - - 16.16% 11.29% 16.76% 16.79%
Announcement Date 4/21/20 1/28/21 4/26/22 2/2/23 2/1/24 - - -
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ArcticZymes Technologies ASA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
23 NOK
Average target price
27.5 NOK
Spread / Average Target
+19.57%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARCTICZYMES TECHNOLOGIES ASA Stock ArcticZymes Technologies ASA
-44.40% 111M
MODERNA, INC. Stock Moderna, Inc.
+17.09% 44.63B
LONZA GROUP AG Stock Lonza Group AG
+44.81% 40.46B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-9.70% 38.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+33.28% 32.27B
CELLTRION, INC. Stock Celltrion, Inc.
-8.98% 27.3B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.37% 26.53B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.11% 14.06B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.33% 12.54B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.26% 11.28B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AZT Stock
  4. Financials ArcticZymes Technologies ASA